Dr. Lal PathLabs Ltd

Dr. Lal PathLabs Ltd announced today the acquisition of a 70% stake in SN Genelab Private Limited (SN Gene) for up to INR 168 Crores, plus performance-linked earn-out capped at INR 31.5 Crores. This strategic move aims to strengthen the company's genomics expertise and expand its advanced diagnostic service portfolio. SN Gene, specializing in diagnostics and genomics, had a turnover of INR 57.96 Crores in FY26. The acquisition is expected to be completed by November 30, 2026, and SN Gene will become a subsidiary of Dr. Lal PathLabs post-completion. This transaction is not a related party transaction.

Dr. Lal PathLabs Ltd announced today that its Board of Directors has approved the acquisition of a 70% stake in SN Genelab Private Limited, a diagnostics genomics company. The deal, valued at up to INR 168 Crores plus performance-linked earn-out, is expected to close by November 30, 2026. This strategic acquisition aims to enhance Dr. Lal PathLabs' expertise in genomics and expand its advanced diagnostic service offerings. SN Genelab reported a turnover of INR 57.96 Crores in FY26. Post-acquisition, SN Genelab will become a subsidiary of Dr. Lal PathLabs.

Dr. Lal Ventures Private Limited, a wholly-owned subsidiary of Dr. Lal PathLabs Ltd, has completed its subscription of a 30% stake in Neuome Technologies Private Limited. This investment, initially approved by the board on July 24, 2026, was finalized on August 27, 2026. Following this transaction, Neuome Technologies Private Limited is now considered an associate of Dr. Lal PathLabs Ltd. The company has stated that all necessary disclosures as per SEBI regulations were made in the earlier intimation dated July 24, 2026. This move signifies a strategic investment by Dr. Lal PathLabs into the technology sector through its subsidiary.

Dr. Lal PathLabs FZCO, a wholly-owned subsidiary in Dubai, has incorporated a new entity named "Dr Lal PathLabs Indomed LLC" in Tashkent, Uzbekistan, on August 19, 2026. The subsidiary will subscribe to 70% of the new entity's share capital. This move aims to strengthen the Group's presence in Tashkent and expand its diagnostic services business. The incorporation is a step towards establishing a new operational base in Uzbekistan.

Dr. Lal PathLabs Ltd has announced the completion of the tenure for its Independent Director, Mr. Gurinder Singh Kalra (DIN: 10197218). Mr. Kalra will cease to hold his position effective July 26, 2026, after completing his current term. The company has submitted the necessary intimation as per Listing Regulations. No further details regarding his profile or relationships were provided as this is a cessation due to tenure completion.

Dr Lal PathLabs Limited announced its un-audited financial results for the quarter ended June 30, 2026. The company reported a consolidated revenue of ₹798 Cr, marking a 19.1% increase year-on-year. EBITDA grew by 28.7% to ₹247 Cr with a margin of 31.0%, and Profit After Tax (PAT) stood at ₹170 Cr, a 27.2% increase, with a margin of 21.4%. The company also declared an interim dividend of 50% (₹5 per share). Key strategic moves include the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for up to GHS 45.6 million, and a 30% stake in Neuome Technologies Private Limited for up to ₹3.5 Cr. Cash and cash equivalents were reported at ₹1,693 Cr as of June 30, 2026.

Dr. Lal PathLabs Ltd's Board of Directors met on July 24, 2026, approving un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also declared an interim dividend of ₹5 per equity share for FY 2026-27, with a record date of July 30, 2026. Additionally, stock options were approved for eligible employees under the Restricted Stock Unit Plan 2025. The board also took note of acquisitions approved by its wholly-owned subsidiaries: Dr Lal PathLabs FZCO, Dubai, approved a stake acquisition in Sunshine Healthcare Limited (Ghana), and Dr. Lal Ventures Private Limited approved a stake acquisition in Neuome Technologies Private Limited.

Dr. Lal PathLabs Ltd's Board of Directors convened on July 24, 2026, approving the un-audited financial results for the quarter ended June 30, 2026. The board also declared an interim dividend of ₹5 per equity share for FY 2026-27, with a record date of July 30, 2026. Additionally, stock options were approved for eligible employees under the Restricted Stock Unit Plan 2025. The board was also informed of two key acquisitions: Dr Lal PathLabs FZCO, Dubai (a wholly-owned subsidiary) approved the acquisition of a stake in Sunshine Healthcare Limited, Ghana, and Dr. Lal Ventures Private Limited (a wholly-owned subsidiary) approved the acquisition of a stake in Neuome Technologies Private Limited.

Dr. Lal PathLabs Ltd's Board of Directors met on July 24, 2026, approving un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also declared an interim dividend of ₹5 per equity share for FY 2026-27, with a record date of July 30, 2026. Additionally, stock options were approved under the Employee Restricted Stock Unit Plan 2025. The board also noted acquisitions approved by its wholly-owned subsidiaries: Dr Lal PathLabs FZCO, Dubai, approved a stake acquisition in Sunshine Healthcare Limited (Ghana), and Dr. Lal Ventures Private Limited approved a stake acquisition in Neuome Technologies Private Limited.

Dr. Lal PathLabs Ltd's Board of Directors met on July 24, 2026, approving the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also declared an interim dividend of ₹5 per equity share for FY 2026-27, with a record date of July 30, 2026. Additionally, stock options were granted under the Employee Restricted Stock Unit Plan 2025. The board also noted acquisitions approved by its wholly-owned subsidiaries: Dr Lal PathLabs FZCO, Dubai, approved a stake acquisition in Sunshine Healthcare Limited (Ghana), and Dr. Lal Ventures Private Limited approved a stake acquisition in Neuome Technologies Private Limited.